Project Main Details
• Audio files must be delivered via email
But how do you determine which patients are at risk?
Baseline Ejection Fraction, or EF, is the most powerful predictor of long-term mortality
Following a cardiac event, the risk of SCD is highest in the first 90 days.
It has been demonstrated in numerous clinical studies
that low-EF post-MI, post-PCI, and heart failure patients have high mortality in the early period – including mortality from SCD.
Following an MI, the majority of mortality occurs in the first 3
The VALIANT Trial clearly demonstrated the high, early risk of SCD after an MI.
Alternate (if we do not want to name “VALIANT”) A trial of more than 14,000 patients clearly demonstrated the high, early risk of SCD after an MI.
Multiple large studies show that high-risk Post-PCI patients have 90-day mortality rates ranging from 11 to 32 percent.
If need extra VO:
When other risk factors are considered in addition to EF, the likelihood of death increases.
The presence of heart failure only exacerbates the problem. Post-MI patients with heart failure are at 4 to 6 times greater risk of sudden cardiac death in the first 30 days after MI.
Mortality Rates in heart failure patients are high in the first six months following a diagnosis, with 54% due to sudden cardiac death.
Bottom Line: In the early period after a cardiac event, Low-EF patients need protection from sudden cardiac death.
The LifeVest® wearable cardioverter defibrillator is a proven therapy for temporary protection of at-risk patients.
A prospective registry of 2,000 US patients assessed LifeVest outcomes
among ischemic, non-ischemic, and congenital heart failure patients.
2.1% of all patients experienced sustained VT/VF.
The LifeVest provides patients with protection during the vulnerable period,
to determine if their EF will improve or if they will require long-term SCD protection.
One-year survival following use of the LifeVest across all patients was high, with no meaningful difference in survival between ischemic and non-ischemic patients.
(NOTE for discussion: does second part of statement add anything?)
Use of the LifeVest is recommended across a wide variety of patient types,
including Post-MI, with or without revascularization,
newly diagnosed non-ischemic cardiomyopathy and heart failure,
and other conditions for which an ICD is not appropriate.
The wearable defibrillator has been included in guidelines and recommendations from international cardiology societies.
On any given day, tens of thousands of people are protected from sudden cardiac death by wearing the LifeVest.
Closing Option 1:
Prescribe the LifeVest. Together, we can identify patients at high risk and prevent sudden cardiac death.
NOTE: This frame optional if “Prescribe the LifeVest” is too strong/too direct
Closing Option 2 (if “Prescribe the LifeVest is too strong”)
Identify Patients At Risk.
Prevent Sudden Cardiac Death.
Together, we can protect your patients and save lives.
Voice123 Team Comments
Voice123 consultations with this voice seeker regarding this project and/or other projects by this voice seeker, via phone, chat, and/or email.
This project - phone.
Previous projects - phone.
This project - email or chat.
Previous projects - email or chat.
Note: Voice123 strives to establish the legitimacy of all projects posted. However, Voice123 subscribers and users are responsible for confirming information stated by prospective voice seekers, agents and/or clients. Voice123 subscribers and users assume all liability for use of any information found through Voice123, or any of its publications.
This page contains the most important details of this project. If you find the information on this project inaccurate or inappropriate, please let us know by contacting us.